European Leukemia Trial Registry
Trial: BRIDGE

More Details
Scientific Title Clofarabin salvage therapy in patients with relapsed or refractory AML: The BRIDGE Trial
Short Title BRIDGE
Trialgroup SAL
Type of Trial multicentric, single-group, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 40 years
Status Closed
Start of Recruitment 28.02.2011
Contactperson

principal investigator
Schetelig, Prof. Dr. med., Johannes
Tel: +49 (0)351 458-15604
Fax: +49 (0)351 449210-637
Email: johannes.schetelig@uniklinikum-dresden.de

Shortprotocol Shortprotocol
Remark www.sal-aml.org
created 21.10.2011 Johannes Kraus
changed 28.08.2014 Johannes Kraus
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org